Dextromethorphan (DXM) and Tramadol
Dextromethorphan (DXM) is a medication primarily used as a cough suppressant in over-the-counter (OTC) cough and cold medications. It is part of the morphinan class of medications but has a variety of effects depending on the dose and context of use.
DXM and its primary active metabolite, dextrorphan, act as antagonists of the NMDA (N-methyl-D-aspartate) receptor. The NMDA receptor is a subtype of glutamate receptor involved in synaptic plasticity, learning, and memory. By blocking this receptor, DXM can produce dissociative effects, which are sometimes compared to those of other dissociative anesthetics like ketamine or PCP.
DXM also has serotonin reuptake inhibitory properties. This means it increases the level of serotonin, a key neurotransmitter in mood regulation, by preventing its reabsorption into neurons. This property is why DXM can potentially cause serotonin syndrome.
Besides DXM acts as an agonist at sigma-1 receptors, which are involved in modulating the release of neurotransmitters and are implicated in the regulation of mood, cognition, and neuroprotection. The role of sigma-1 receptors in DXM's overall effects is still being studied but may contribute to its dissociative and euphoric properties.
At higher doses, DXM can also interact with other receptors in the brain, including nicotinic acetylcholine receptors and opioid receptors, although its affinity for these is much lower. These interactions may contribute to some of the drug’s more complex effects.
Tramadol is a synthetic opioid used primarily for the treatment of moderate to moderately severe pain. It has a unique mechanism of action that distinguishes it from many other opioids, as it not only affects opioid receptors but also influences the neurotransmitter systems in the brain.
Tramadol acts as a partial agonist at the µ-opioid receptor (mu-opioid receptor). These receptors are part of the endogenous opioid system, which modulates pain perception, mood, and reward. By activating these receptors, tramadol helps to reduce the sensation of pain.
In addition to its opioid activity, tramadol inhibits the reuptake of serotonin and norepinephrine. These neurotransmitters are involved in mood regulation and the modulation of pain. By increasing their levels in the synaptic cleft, tramadol can enhance the descending inhibitory pathways in the spinal cord, which reduces pain signals before they reach the brain. This dual action makes tramadol similar in some respects to certain antidepressants, particularly those of the SNRI (serotonin-norepinephrine reuptake inhibitor) class.
Tramadol is metabolized in the liver by the enzyme CYP2D6 into an active metabolite called O-desmethyltramadol (M1), which has a much stronger affinity for the µ-opioid receptor than the parent compound. This metabolite is primarily responsible for the opioid effects of tramadol. However, the efficiency of this conversion can vary among individuals due to genetic differences in the CYP2D6 enzyme, leading to variability in the drug's effectiveness and risk of side effects.
Combining DXM and tramadol can result in significant and potentially dangerous effects due to the interaction of their pharmacological mechanisms.
- Increased Risk of Serotonin Syndrome. Both DXM and tramadol inhibit the reuptake of serotonin, leading to increased levels of this neurotransmitter in the brain. When taken together, this can significantly raise the risk of serotonin syndrome, a potentially life-threatening condition. Symptoms include confusion, agitation, rapid heart rate, high blood pressure, fever, muscle rigidity, tremor, and in severe cases, seizures, coma, or death.
- Enhanced CNS Depression. Both drugs can depress the central nervous system (CNS). When used together, the risk of severe CNS depression increases, leading to profound drowsiness, respiratory depression, and potentially fatal overdose. This is particularly concerning if either drug is used in higher-than-prescribed doses or in combination with other CNS depressants like alcohol or benzodiazepines.
- Lowered Seizure Threshold. Tramadol on its own is known to lower the seizure threshold, making seizures more likely, especially in those with a history of seizures. DXM can exacerbate this effect, further increasing the risk of convulsions, particularly at higher doses.
- Gastrointestinal Issues. Both DXM and tramadol can cause gastrointestinal side effects such as nausea, vomiting, and constipation. The combined use may exacerbate these effects, potentially leading to severe discomfort or complications, especially in vulnerable individuals.
- Psychiatric Effects. The combination may also lead to increased risk of psychiatric disturbances such as anxiety, hallucinations, and in severe cases, psychosis, particularly due to the dissociative properties of DXM at high doses and tramadol's impact on mood regulation.
All things considered, we recommend avoiding this combination under any conditions.
Last edited by a moderator: